title: A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction.
abstract: OBJECTIVE
  We developed a new method-transmyocardial drilling revascularization (TMDR) with absorbable stent incorporated with basic fibroblast growth factor (bFGF) and heparin. The present study tested the effect of this method with transplantation of bone marrow-derived stem cells (BMSCs) in acute myocardial infarction.
  
  
  RESULTS
  Infarction was produced in mini-swine by ligating the left anterior descending (LAD) coronary artery. TMDR of 3.0 mm in diameter was made by mechanical drilling in the infarcted area. The animals that had LAD ligation were divided into six groups according to the procedures followed (n = 6 in each): control; T (TMDR); C (cell implantation); TS (TMDR+stent implantation); TC (TMDR+cell implantation); TSC (TMDR+stent implantation+cell implantation). Left ventricular (LV) function, myocardial perfusion, vascular density, and histological and morphological analyses were evaluated pre-operatively and at 30 min and 6 weeks post-operatively. Six weeks after operation, the above indices were significantly better in the TSC group than in other groups (P < 0.001 compared with the control group, and P < 0.05 or 0.01 compared with the TS and TC groups), although TS and TC also showed better results than the control group (P < 0.05).
  
  
  CONCLUSIONS
  We have demonstrated in a pig model that an intramyocardial stent implanted with slow release of bFGF, heparin, and BMSC transplantation may significantly increase LV function, cardiac blood flow, and vascular density. Therefore, the present study may provide a new method for the surgical treatment of myocardial infarction.
authors: Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
authors: Ying
authors: Y
authors: Wang
authors: Xiao-Cheng
authors: XC
authors: Liu
authors: Guang-Wei
authors: GW
authors: Zhang
authors: Jian
authors: J
authors: Zhao
authors: Jie-Min
authors: JM
authors: Zhang
authors: Rong-Fang
authors: RF
authors: Shi
authors: Yun-Zhou
authors: YZ
authors: Huang
authors: Chun-Hua
authors: CH
authors: Zhao
authors: Tian-Jun
authors: TJ
authors: Liu
authors: Cun-Xian
authors: CX
authors: Song
authors: Feng
authors: F
authors: Lü
authors: Qin
authors: Q
authors: Yang
authors: Guo-Wei
authors: GW
authors: He
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D003331:Coronary Vessels / Q000502:physiology; D004195:Disease Models, Animal; D054855:Drug-Eluting Stents; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D045164:Mesenchymal Stem Cell Transplantation; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000502:physiology; D012039:Regional Blood Flow / Q000502:physiology; D013552:Swine; D013556:Swine, Miniature; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology / Q000628:therapy
chemical_list: D005343:Fibrinolytic Agents; D016222:Fibroblast Growth Factor 2; D006493:Heparin